INVION ACHIEVES MILESTONE FOR PHASE I/II HUMAN CLINICAL TRIAL IN NON-MELANOMA SKIN CANCERS
Invion completes lodgement of the trial application with the Human Research Ethics Committee (HREC).
Invion partners with Veracity Clinical Research to enrol patients for the skin cancer trial in Queensland with first patient recruitment expected in early 2024.
Adaptive trial design gives Invion greater flexibility to produce efficacy results on top of safety data in its Phase I/II non-melanoma skin cancer trial.The above was announced via the Invion Investor Hub.
I can't believe ASX did not think it was significant enough as per the response from Invion
"The ASX knocked back our announcement as it deemed it isn't material enough, hence we had to release it through our Investor Hub"
INVION ACHIEVES MILESTONE FOR PHASE I/II HUMAN CLINICAL TRIAL IN...
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.12M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $5.226K | 1.262M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 22452399 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 6922025 | 23 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IVX (ASX) Chart |